| Name | Title | Contact Details |
|---|
Overlook House is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are committed to the people of our community, to help them overcome challenges and reach their greatest potential by providing quality care, people-oriented services and comfort.
Homeward is rearchitecting rural health and care for the 60 million Americans living in rural communities. Homeward employs a multidisciplinary care team, available both virtually and on the ground via mobile care units, with in-home remote monitoring to better connect patients to high-quality, affordable and comprehensive care. Today, the company partners with Medicare Advantage plans, taking on the full risk of their members to improve outcomes and reduce costs.
Aimmune is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. We aim to address food allergies by providing a treatment option that goes beyond the current protocols of avoiding exposure to food allergens and carrying epinephrine for administration in case of accidental exposure. Our CODIT™ system is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. In oral immunotherapy (OIT), a very small amount of an allergen is administered on a daily basis and then regularly increased until desensitization to a certain amount of the allergen has been achieved. We plan to develop and commercialize standardized, pharmaceutical-grade food allergens for our CODIT™ (characterized oral desensitization immunotherapy) system, our system for OIT. Our lead product candidate, AR101, is a standardized, complex mixture of 13 naturally occurring proteins and pharmaceutical-grade ingredients that, with the CODIT system of gradual, controlled updosing and ongoing maintenance dosing, has obtained meaningful desensitization to peanut allergens in our initial clinical studies.
At DCHS, our mission is simple: to improve health every day. We are seeking providers to join our group who will share in our mission and help to cultivate our vision…to be the healthcare provider of choice for the communities we serve. Be an integral partner with one of the country`s top-ranked, most respected healthcare systems. As a system, DCHS is dedicated to purchasing the most advanced technology, operating state-of-the-art facilities and introducing new and innovative models of care. Vision, passion, perseverance, knowledge, skill, dedication, warmth, caring, technology, and people, have come together like a finely woven tapestry to create a healthcare experience for our patients that we call the Dickinson Difference.